

DOB: _____

Health Summary

Date: _____

MRN: _____

Name: _____

Local Clinic: _____

Phone #: _____ Is text okay?

Alternate Contact: _____

Medications²: _____

Checked DRUG interactions Yes No

Allergies: _____

Before Treatment: PCP Notified Fibroscan _____

Immediately prior: Pregnancy test

Uric Acid (with ribavirin)

Within 1 month: CBC

CMP

PT/INR

HCV RNA

Within 3 months: Genotype confirmation

HBV DNA (if HBcAb +)

Within 6 months: AFP

A1C or Fasting Glucose

Vitamin D 25OH total

Within 1 year: HIV screening

NS5a RAS (prior DAA tx failure

or if cirrhotic & treating with

Eplusa)

HBcAb & HBsAg

Once: _____

Tx Regimen: _____

Pertinent Medical History:

Previous hepatitis C treatment¹ Yes No

Specify: _____

Cirrhosis¹ Yes No

Child-Pugh Score: _____

Other Liver Disease¹ Yes No

Specify: _____

Pulmonary Disorders¹ Yes No

Specify: _____

Cardiac Disease/DVT/PE^{1,2} Yes No

Specify: _____

Taking Amiodarone? Yes No

PPI/H2 blocker/Antacid use² Yes No

Specify: _____

Autoimmune Disorders² / Organ Transplant²

Yes No

Specify: _____

Cancer Yes No

Specify: _____

Current infection¹ Yes No

Specify: _____

High Blood Pressure Yes No

High Cholesterol Medication?² Yes No

Kidney Disease² Yes No

Anemia^{1, 2} Yes No

Current TB Treatment² Yes No

Diabetes Specify Type 1 or 2 Yes No

HIV or AIDS¹ Yes No

Seizure Disorder² Yes No

Mental Health Conditions Yes No

Specify: _____

Screen & Review: AUDIT-C ___ PHQ-9 ___

Vaccine Status: Hepatitis A ___ Hepatitis B ___

Other vaccines as appropriate:

Flu (annually)

PCV-13 (≥ age 65 or immunosuppressed)

PPSV-23 (≥ age 50 AN/AI or high risk)

Td (once every 10 years) **OR** Tdap (once)

Recombinant Zoster (≥ age 50)

Birth Control Methods: _____

Females: LMP: _____ Pregnant? Yes No

Males: Partner pregnant? (ribavirin only) Yes No

Any upcoming events which might prevent you from completing HCV treatment? Yes No

Insurance status: _____

1- Further evaluation as indicated; consult Liver Disease Specialist prior to treatment.

2- Check drug interactions to treatment drugs. Further evaluation as indicated.